Abstract
Aim: This study aimed to report the efficacy and safety of trans-arterial chemoembolization (TACE) plus lenvatinib and camrelizumab in patients with advanced hepatocellular carcinoma (HCC). Methods: This retrospective study enrolled 22 patients with advanced HCC from March 2018 to December 2019. All the patients received comprehensive treatment with TACE plus lenvatinib followed by camrelizumab. Overall survival (OS) and progression-free survival (PFS) were calculated and analysed using the Kaplan-Meier method and log-rank test. Treatment response and adverse events (AEs) were also evaluated. Results: The objective response rate (ORR) and disease control rate (DCR) for the whole cohort were 68.2 and 100% at the first month and 72.7 and 95.5% at the third month, respectively. The median OS was 24 months (95% CI, 20.323–27.677 months), and the median PFS was 11.4 months (95% CI, 8.846–13.954 months). The majority of treatment-related adverse reactions were mild or moderate, except for 4 that developed to grade 3–4 (3 reactions of grade 3, 1 reaction of grade 4). No deaths or other serious adverse reactions occurred. Conclusion: Trans-arterial chemoembolization plus lenvatinib and camrelizumab shows good results incontrolling tumour progression and prolonging median OS in patients with advanced HCC.
Highlights
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide (Ferlay et al, 2015)
We aimed to evaluate the therapeutic efficacy of trans-arterial chemoembolization (TACE) plus lenvatinib and camrelizumab in advanced HCC patients
Over the whole therapy cycle, only 3 (13.6%) patients had a reduction in lenvatinib, and 1 (4.5%) patient had a temporary suspension of camrelizumab as a result of not being well tolerated
Summary
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide (Ferlay et al, 2015). It represents approximately 90% of primary liver cancers and constitutes a major global health problem (Galle Peter et al, 2018). Due to its insidious onset and nonspecific symptoms, HCC is often diagnosed at a late or advanced stage. Lenvatinib has been approved for first-line treatment of patients with unresectable advanced HCC in many countries. Since 2018, lenvatinib has become another first-line systemic treatment for HCC patients and is deemed an alternative to sorafenib due to its comparable efficacy (Kudo et al, 2018)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
